Recent 8-K filings for VREX

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Varex Q2 revenue $216M (+1% YoY), GAAP EPS -$0.19; guides FY26 rev $860-880M, non-GAAP EPS $0.80-1.00

  Revenue $216M (+1% YoY); Medical $156M, Industrial $60M.

• March 16, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.01item 1.02item 2.03item 8.01item 9.01 ◈ Material Agreements ×3◈ Debt Financings

  Varex closes $490M credit facility, redeems $368M 7.875% notes due 2027

  New facility includes $350M term loan, $100M revolver, $40M delayed draw; matures March 13, 2031.

• February 13, 2026, 6:59 PM ET other material materiality 0.15 neutral item 5.07

  Varex Imaging shareholders elect all seven director nominees at 2026 annual meeting

  All seven director nominees elected with >34M votes for each; broker non-votes ~3.4M.

• February 10, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Varex Q1 revenue $210M (+5% YoY), Non-GAAP EPS $0.19, guides Q2 rev $210-225M

  GAAP net income $0.05 per diluted share; Non-GAAP EPS $0.19 (up from $0.10 YoY).

• November 18, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Varex Q4 revenue $229M (+11% YoY); Non-GAAP EPS $0.37; guides Q1 $200-215M

  Q4 FY25 revenue $229M, up 11% YoY; Medical segment $152M (+5%), Industrial $77M (+25%).

• September 11, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02

  Varex SVP & CLO Kimberley Honeysett to transition; advisory role through Dec 2027

  Kimberley Honeysett steps down as CLO effective Oct 3, 2025, then remains as non-executive employee/advisor until Dec 12, 2027.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Varex Q3 revenue $203M beats guidance; GAAP loss $(2.15), non-GAAP profit $0.18

  Revenue of $203M down 3% YoY but above high-end guidance; Industrial segment up 1% to $61M, Medical down 4% to $142M.

• May 8, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Varex Q2 revenue $213M (+3% YoY); China tariff pause cuts Q3 outlook to $180-200M

  GAAP EPS $0.17, Non-GAAP EPS $0.26 vs $0.16 prior year.

• April 4, 2025, 7:59 PM ET regulatory materiality 0.60 negative item 7.01

  China MOFCOM launches anti-dumping probe on CT X-ray tubes; Varex could be impacted

  China MOFCOM announced anti-dumping investigation into medical CT X-ray tubes from US and India.

• February 14, 2025, 6:59 PM ET other materiality 0.25 neutral item 5.03item 5.07item 9.01

  Varex stockholders approve officer exculpation amendment; re-elect all directors

  All seven director nominees elected with 34.2M to 35.0M votes for; brokers non-voted 2.6M shares.

• February 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Varex Q1 FY2025 revenue up 5% YoY to $200M; GAAP net loss $0.01/sh, Non-GAAP EPS $0.07

  Medical segment revenue $145M (+3% YoY); Industrial segment revenue $55M (+10% YoY).

• January 6, 2025, 6:59 PM ET debt materiality 0.30 neutral item 1.02

  Varex terminates $20M equipment credit facility after senior secured notes offering

  Equipment Credit Agreement with Zions terminated effective Dec 20, 2024, confirmed Jan 3, 2025.

• December 23, 2024, 6:59 PM ET debt materiality 0.75 neutral item 1.01item 1.02item 2.03item 8.01item 9.01

  Varex closes $125M 7.875% senior secured notes due 2027 for convertible note repayment

  $125M aggregate principal at 101.5% of par, 7.875% coupon, maturing 2027.

• December 17, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 8.01item 9.01

  Varex prices $125M add'l 7.875% senior secured notes due 2027 to repay convertible notes

  $125M aggregate principal of 7.875% senior secured notes due Oct 2027 priced at 101.5% of par.

• November 19, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Varex Q4 FY24 revenue $206M; GAAP EPS loss $1.22, non-GAAP EPS $0.19

  GAAP net loss of $1.22 per diluted share; non-GAAP EPS of $0.19, down from $0.45 YoY.

• September 11, 2024, 7:59 PM ET debt materiality 0.55 neutral item 8.01

  Varex amends credit agreement to relax covenants on convertible note payments and leverage

  Amendment dated Sept 11, 2024 with Zions Bancorporation modifies Payment Conditions to allow restricted payments up to greater of 50% of CNI or $50M when leverage >2.50x.

• August 1, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Varex Q3 FY2024 revenue down 10% YoY; Q4 guidance weak

  Revenue $209M (-10% YoY); GAAP EPS $0.03, Non-GAAP EPS $0.14 vs $0.37 YoY.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Varex Q2 revenue $206M, down 10% YoY; lowers H2 outlook due to China softness

  Revenue $206M, down 10% YoY; GAAP EPS $0.03, Non-GAAP EPS $0.16 (down from $0.26).

• March 27, 2024, 7:59 PM ET debt materiality 0.55 neutral item 1.01item 1.02item 2.03item 8.01item 9.01 ◈ Material Agreements ×2◈ Debt Financings

  Varex closes $155M senior secured revolving credit facility with Zions, replaces prior ABL

  New $155M senior secured revolving credit facility matures September 26, 2027.

• February 9, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01 ◈ Shareholder Votes ×4

  Varex Imaging shareholders elect directors, approve amended equity plan at 2024 annual meeting

  All seven director nominees elected with ~92% of shares represented; vote results filed.

• February 6, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases ×3

  Varex Q1 FY2024 revenue $190M (-8% YoY), GAAP loss $0.01/sh, non-GAAP EPS $0.06

  Revenue $190M, down 8% YoY; Medical segment $140M (-13%), Industrial $50M (+10%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

3 positive 5 negative 13 neutral

source · VREX on sec.gov